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Abstract
There is an ongoing debate
regarding role of surgery for
recurrent glioblastoma
multiforme (GBM). Older
literature hinted at only modest
survival benefits with surgery and
a high rate of morbidity.
However, more recent literature
suggests better survival that may
be attributed to better surgical
techniques and better options in
adjuvant treatment. Herein the
authors review recent literature
with regards to the possible role
of surgery in recurrent GBM and
also look into the key factors
impacting second surgery.
Keywords: Recurrence, brain tumour, Glioblastoma
multiforme.
Introduction
Glioblastoma multiforme (GBM) is the commonest and
one of the most aggressive primary brain tumour, and
despite all the advances in diagnosis and management
continues to be uniformly fatal.1 The presently accepted
protocol requires aggressive surgery, followed by
chemotherapy and radiation therapy for best
outcomes. However, the tumour invariably recurs,
raising the question for second line management,
including reoperation. Most GBMs recur locally in the
resection cavity, and are therefore potential candidates
both for surgery as well as adjuvant chemo-radiation
therapy.2 Although many studies have suggested
improved outcomes with re-operations in case of
recurrence, there are also reports of substantial
morbidity in re-operations.
Review of Evidence
A systematic review published in 2014 provides level II
evidence that reoperation is beneficial in symptomatic
patients with locally recurrent or progressive high-
grade gliomas.3 The study also recommended the use
of preoperative factors like location of recurrence in
eloquent brain regions, Karnofsky Performance Status
(KPS) and tumour volume; to be considered when
evaluating a patient for reoperation.3 The role of
extent of resection (EOR) has also remained a topic of
debate and the various options vary from debulking
(maximal safe resection), border resection (resection
margins at the tumour edge), gross total resection and
extended resection (resection margins 1-2 cm away
from tumour edges). Some authors have also
predicted survival outcomes based on the pattern of
recurrence such as local recurrence (LR) at the site of
primary resection cavity, or distant recurrence (DR) at
a distant site. Bonis et al., reported statistically
significant improvements in rates of tumour
progression after border resection (p<0.05) and
reported survival outcomes for 60 patients with local
recurrence to be 16-months as compared to 35-
months for 15 patients with distant recurrence (p
0.06).4 Oppenlander et al., reported EOR thresholds for
recurrent GBM concluding that a significant
improvement in overall survival (OS) was achieved
with 80% EOR. The median progression free survival
(PFS) following reoperation was estimated at 5.2
months, while median OS was 1.9 years for same
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Figure-1: (a,b) Post-operative MRI T1W pre and post-contrast axial images, showing gross total resection of GBM.
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population. They also reported an extremely
promising 2.5 years OS in a subset with EOR >97% for
recurrent GBM, with age, KPS, and EOR as predictors of
survival (P < 0.05).5
De Bonis et al., in another paper also compared
outcomes for 76 consecutive patients with recurrent
glioblastoma. Treatment was categorized into surgical
resection alone (17 patients), chemotherapy alone (24
patients), combined approach (16 patients) and no
intervention (19 patients). They concluded that
patients with a KPS >70 had a considerably prolonged
survival (9 months vs. 5 months, p <0.05) and OS was 6
months for patients in surgical resection only, 5
months for patients that received no intervention, 8
months for patients treated with chemotherapy alone,
while 14 months for patients treated with surgery and
adjuvant therapy combined (p <0.05). Their surgical
morbidity however, was substantial (16 out of 33
patients, 48%).6 Skeie et al., reported their comparison
between gamma knife surgery (GKS) and surgery for
recurrent GBM. The study had 32 patients who
underwent GKS alone, 26 underwent surgery alone,
and 19 received both treatment modalities. They
reported median time from second intervention to
tumour progression was significantly longer after GKS
than after surgery (P <0.05). Median survival after
radiosurgery was12 months for the 51 patients
receiving GKS (with or without surgery) in comparison
to 6 months for surgery only (hazards ratio 2.4). They
also reported fewer complications after GKS (9.8% vs.
25.2%).7 Brandes et al., in 2016, analyzed OS in 270
patients who received surgery for recurrent GBM. Of
these patients, 128 had
complete resection and
142 had partial resection.
Median survival from
surgery was 11.4 months
and age <70 years (p
<0.05), MGMT methylation
status (p <0.05), and EOR (p
<0.05) were associated
with better survival.8
Sughrue et al., studied the
clinical outcome with EOR
for recurrent GMB in a
cohort of 105 patients. Post-
surgical analysis was based
on gadolinium contrast-
enhanced MRI that was
available in 59 patients who
were re-operated. In these
patients, complete
resection of contrast-enhancing tumour (N=40) verses
residual detection of contrast enhancement (N=19) was
correlated with improved survival and quality of life
(QoL). Incomplete tumour resection was correlated with
poorer survival compared with patients who did not
undergo surgery. No significant difference in QoL was
found in these two groups. They concluded that
reoperation improves outcomes if complete resection
of contrast-enhancing tumour is attained.9 The
DIRECTOR trial reported median PFS of 7.8 months, 6
months, and 4.8 months following the second, third,
and more craniotomies for glioblastomas, respectively.
The study also concluded that previous PFS is not a
predictor of PFS the next surgery will provide the
patient.10 Surgery, re-irradiation and systemic
chemotherapy provided short-term disease control and
modest survival benefit. 
Conclusion
The authors conclude that there is a definite role of
surgery in the management of recurrent GBM. The
factors to be considered before opting for reoperation
are (i) age of the patient, (ii) KPS score, (iii) eloquent vs.
non-eloquent location of recurrence, (iv) MGMT
methylation status. Operative factors associated with
better survival include extent of resection >80% (EOR)
and distant site of recurrence. Repeat surgery can
improve both OS and PFS.
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